
Longeveron (LGVN) stock closed significantly higher on March 10 after the biotech firm announced a private placement generating about $30 million from institutional and accredited investors.
The financing comprises an initial $15 million tranche with potential for an additional $15 million contingent upon achieving specific milestones related to the anticipated Phase 2b ELPIS II clinical trial.